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ABSTRACT
Context:
Currently, systematic evidence of prevalence of clinically significant depressive symptoms in people
with extremely short prognoses is not available to inform its global burden, assessment, and
management.
Objectives:
To determine the prevalence of clinically significant depressive symptoms in people with advanced
life-limiting illnesses and extremely short prognoses (range of days to weeks).
Methods:
A systematic review and meta-analysis (random effects model) were performed (PROSPERO:
CRD42019125119). MEDLINE, Embase, PsycINFO, CINAHL, and CareSearch were searched for studies
(1994-2019). Data were screened for prevalence of clinically significant depressive symptoms
(assessed using validated depression-specific screening tools or diagnostic criteria) of adults with
advanced life-limiting illnesses and extremely short prognoses (defined by survival or functional
status).
Quality assessment was performed using the Joanna Briggs Institute Systematic Reviews Checklist
for Prevalence Studies for individual studies, and Grading of Recommendations Assessment,
Development and Evaluation (GRADE) across studies.
Results:
Thirteen studies were included. The overall pooled prevalence of clinically significant depressive
symptoms in adults with extremely short prognoses (n = 10 studies; extremely short prognoses: N =
905) using depression-specific screening tools was 50% (95%CI: 29%-70%; I2 = 97.6%). Prevalence of
major and minor depression were 10% (95%CI: 4%-16%) and 5% (95%CI: 2%-8%), respectively. Major
limitations included high heterogeneity, selection bias and small sample sizes in individual studies.
Conclusions:
Clinically significant depressive symptoms were prevalent in people with advanced life-limiting
illnesses and extremely short prognoses. Clinicians need to be proactive in the recognition and
assessment of these symptoms to allow for timely intervention.
Keywords:
Palliative Care; Prognoses; Depression; Prevalence; Systematic Review; Meta-analysis
Running Title: Depression in the Dying – A Systematic Review

KEY MESSAGES
Clinically significant depressive symptoms affected half of the people with extremely short
prognoses. Results provide clinicians, policy-makers & funders, researchers and general public with
new information about the high prevalence of clinically significant depressive symptoms in the last
days-to-weeks of life, highlighting the need for pro-active recognition, assessment and management.

INTRODUCTION
Depression is a complex and debilitating condition often seen in the people with advanced lifelimiting illnesses. For individuals affected at the end-of-life, clinical depression can amplify suffering,
limit capacity for pleasure, meaning, and engagement with their loved ones (1-3). It may also be
associated with a desire for hastened death (4).
Assessing and managing depressive symptoms in the setting of advanced life-limiting illnesses can be
complex. A key factor in the complexity stems from the amorphous use of the terminologies of
‘depression’ and ‘palliative care population’ in the literature. In fact, this term “depression” can
imply: 1) a symptom of low-mood state; 2) depressive syndromes consisting of a collection of lowmood related symptoms (e.g. guilt, suicidal ideation, or anorexia) secondary to various mental
disorders or; 3) specific depressive disorders (e.g. major depressive disorder) defined by the goldstandard diagnostic criteria (5). These diagnostic criteria include Diagnostic and Statistical Manual of
Mental Disorders (DSM) or International Classification of Diseases and Related Health Problems for
depressive disorders (ICD) (6-9). Meanwhile, the studied ‘palliative care population’ can differ
significantly from one study to another due to the absence of a standardised referral system for
palliative care (10). The heterogeneity of definitions and the numerous assessment methods across
the literature complicate the assessment and management of depression at the end-of-life. These
have contributed to the wide range of depression prevalence (2%-30%) found in the general
population with advanced life-limiting illnesses (2, 3, 11-18).
The recognition, assessment and management of depressive symptoms is even more challenging in
the subset of the palliative population who are in the last days to weeks of life (19, 20). This period is
usually characterised by an increasing dependence on others for care, increasing symptom burden
and declining functional scores indicative of one month or less of median survival (19, 21). These
include: Karnofsky Performance Scale (KPS) ≤ 40, Eastern Cooperative Oncology Group (ECOG) 4,
and Palliative Performance Scale ≤ 50 (19, 22, 23). Frailty and associated symptoms (such as severe
fatigue, hypersomnia, and physical weakness) may make it difficult for clinicians to recognise and
assess depressive symptoms, especially in people presenting with depressive disorders for the first
time (3). In this setting, treatment can also be challenging. Psychological therapies may require
adaptation as the patients’ cognition might be impaired with poor concentration or delirium, while
their energy levels and motivation are often limited (19, 24, 25). Engagement in therapy may be too
tiresome for some individuals and the benefits of the therapy may not manifest in time (25). Typical
oral antidepressants might not work soon enough due to the person’s extremely short prognosis
(26), or cannot be swallowed due to frailty (25). Therefore, some clinicians feel a sense of futility in
assessing and managing depressive symptoms of these individuals (20).
As this subset of the palliative population with extremely short prognoses and clinically significant
depressive symptoms has specific challenges and needs, it is important to define its prevalence.
Previous systematic reviews of the prevalence of depressive symptoms in the palliative care and
oncology settings did not explicitly examine prevalence in people with extremely short prognoses
(11, 12). Additionally, studies included in these reviews focused on specialist palliative care and
oncology cohorts (11, 12). Patients with advanced life-limiting illnesses and extremely short
prognoses not known to these services would have been excluded.

For the purpose of this review, consistent with the literature, the term “clinically significant
depressive symptoms” has been used. This term embraces various depressive conditions defined by
either: 1) diagnostic criteria, such as ICD, or DSM (27); and 2) validated depression-specific screening
tool (28-30). It does not include delirium with depressive features. The inclusion of prevalence
defined by depression-specific screening tools would ensure subsyndromal depression are
accounted for – i.e. clinically significant depressive symptoms that fulfill specific cut-offs of screening
tools but not the conventional diagnostic criteria .
Knowledge of the prevalence of clinically significant depressive symptoms in people with extremely
short prognoses would quantify its global burden and inform screening, assessment and impetus for
developing targeted therapies.

Aim
To determine the prevalence of clinically significant depressive symptoms in people with extremely
short prognoses (median survival of ≤ 4 weeks with absolute cut-off of < 2 months) suffering from
advanced life-limiting illnesses, as indicated by survival or functional status data (Karnofsky
Performance Scale [KPS] ≤40 or equivalent) (22, 23, 31, 32).

METHODS
Design & Protocol Registration
Systematic review and meta-analysis were reported according to the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) guidelines (33). This review focusing on prevalence
studies represented the first part of the systematic review protocol prospectively registered in
PROSPERO (CRD42019125119).

Search Strategy
A systematic search of the electronic databases of MEDLINE (OVID), PsycINFO, Embase, CINAHL, and
CareSearch (CareSearch filter utilised via PubMed) for studies published between January 1994 and
February 2019 was performed (last search 27 February 2019). The search was limited to the last 25
years, as 1994 was the year when DSM-IV was assimilated to ICD-10 to ensure congruence (34).
The search strategy included search terms in the domains of [Palliative Care or Advanced LifeLimiting Illnesses] AND [Prevalence] AND [Depression] was used initially in MEDLINE (OVID). The
search terms were then adapted for other electronic databases accordingly (see ‘Search Strategy’ in
Supplementary File 1).
Inclusion criteria for studies were: any setting of care or study design; adults (≥ 18 years) with
advanced life-limiting illnesses and extremely short prognoses in the range of days to weeks defined
by either survival data (absolute survival of <2 months) or functional status indicative of a median
survival of 1 month (equivalent of AKPS ≤ 40 or Eastern Cooperative Oncology Group (ECOG) 4) (22,

23, 31, 32); and prevalence of clinically significant depressive symptoms defined by a validated tool
(e.g. Hospital Anxiety and Depression Scale [HADS]) or a depressive disorder defined by diagnostic
criteria (DSM or ICD or equivalent). In relation to diagnostic criteria, the term “major/minor
depression” will be used in this review to encompass: 1) Both “major/minor depressive disorders”
and “major/minor depressive episodes” in DSM (6, 7) and; 2) “major/minor depression” in ICD (8, 9).
Excluded studies were those not peer-reviewed (e.g. theses); studies with no validated method of
assessing depressive symptoms; studies using measures not specific to depression (e.g. Edmonton
Symptom Assessment Scale); as well as systematic reviews and meta-analyses, case studies, opinion
papers, editorials, study protocols or guidelines. A manual selection for adult, human and English
studies was performed without the use of filters to minimise the risk of missing articles due to
delayed coding issues. The reference lists of relevant systematic reviews and meta-analyses were
hand-searched for eligible studies.

Study Selection
Search results were imported into Endnote X9.2 for duplicate removal, and subsequently exported
to Covidence for title and abstract, and full text screenings (35, 36).
Each study was reviewed by both the primary investigator (WL) and a reviewer from the alternative
reviewer group (MP, CS, EL, AH, DP, MA, SK). Fortnightly calibration session was held to maintain
inter-rater reliability. Reasons for exclusions at full text review were documented. A third
independent reviewer (BD) was involved in resolving conflict.

Data Extraction
Data extracted from individual studies included: country; study design; eligibility of sampled
population; settings; diagnoses; participant demographics; sampling method; definition and number
of participants with extremely short prognoses; depression definition, assessment timing and
method; and number and prevalence of clinically significant depressive symptoms in people with
extremely short prognoses. When necessary, the authors of the publications were contacted for
clarification of the data.
Quality and risk of bias assessments were performed using the Joanna Briggs Institute (JBI) Critical
Appraisal Tools for use in JBI Systematic Reviews - Checklist for Prevalence Studies (for individual
studies) (37, 38) and the principles of Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system (across studies) (39, 40).
The primary investigator (WL) extracted data from all included studies. Alternative reviewers (MP
and AH) checked the validity of extracted data and independently performed quality/bias
assessment of studies by randomly selecting studies using a random number generator. Given that
100% consensus was reached on discussion after randomly reviewing five of the 13 studies,
remaining studies were only reviewed by the primary investigator (WL).

Data Synthesis
Prevalence rates were calculated from the number of cases with clinically significantly depressive
symptoms and extremely short prognoses over total number of cases with extremely short
prognoses in each included study. Random effects models were used in accordance with the method
of Nyaga et al (2014) to produce pooled prevalence estimates for clinically significant depressive
symptoms defined by specific screening tools and diagnostic criteria (41, 42). The I2 statistics were
used to estimate heterogeneity and risk of bias. Potential sources of heterogeneity were further
investigated by use of visual inspection of the data, forest plots and through meta-regression
analysis. Inverted funnel plots and Egger’s tests were performed to assess for small study effects or
publication bias. Analyses were carried out with the function for proportion meta-analysis in STATA
Version 16.0

RESULTS
As outlined in the PRISMA diagram (Figure 1), 7957 studies were identified through the electronic
databases. After removal of duplicates, 5531 studies underwent title and abstract screening, leaving
500 studies for full-text screening. Following this, 13 studies (Table 1) were included for data
extraction, with 57.1% (278 out of 487) full-text screening studies not having data on the sub-group
of interest (people with extremely short prognoses). Hand-searching did not identify any eligible
studies.
Study demographics are illustrated in Table 2. All 13 included studies had a prospective design, with
five studies (43-47) being longitudinal and eight being cross-sectional only (4, 48-54). Two studies
had a combination of malignant and non-malignant diseases (e.g. cardiovascular, respiratory and
other diseases) (52, 54). Ten studies focused on malignant disease only (4, 43, 44, 46-51, 53). Out of
these, one study focused on advanced gynecological cancer (53) and another on lung cancer (46).
Other eight malignant studies involved a combination of various types of cancers (4, 43, 44, 47-51).
Extraction of data of interest from specific malignant or non-malignant conditions in studies
involving combination of conditions was not possible. Only one study focused exclusively on a nonmalignant disease (late stage amyotrophic lateral sclerosis) (45).
Six studies involved inpatients only (4, 43, 47, 48, 53, 54), of which three were palliative care specific
(4, 47, 53). One study was home care only (palliative care specific) (52). Four studies were mixed
settings (44, 49-51), one of which was palliative care specific (49). Two studies did not specify the
setting of care (45, 46).
Mean age reported in eight studies ranged from 58.0 to 70.9 years old. Five studies did not report
mean age. The percentage of males ranged from 36.5% – 69.8% in 11 studies. One study did not
report participant gender (44), and one study only recruited females with advanced gynaecological
cancers (53).
For the definition of extremely short prognoses, seven studies reported functional status equivalent
of AKPS ≤ 40 (median survival of one month) (46-51, 53), and eight studies reported directly on
survival data (4, 43-45, 47, 49, 52, 54). Two studies reported both survival and functional status data
(47, 49).

Ten studies defined clinically significant depressive symptoms using a specific tool: Patient Health
Questionnaire 8 or 9 [PHQ-8 or 9] (n = 5) (44, 45, 50, 51, 54), HADS (n = 4) (43, 46, 49, 53), and
Depression Rating Scale [DRS] (n = 1) (52). Four studies used diagnostic criteria (DSMIIIR, IV or V) (4,
47, 48, 54), while one study used both PHQ-9 and DSMV (54).

Prevalence of Clinically Significant Depressive Symptoms
The prevalence of clinically significant depressive symptoms in people with life-limiting illnesses and
extremely short prognoses was analysed with reference to tools, diagnostic criteria and risk of bias.
Tools
1. ≥Mild or Minor Severity (PHQ8/9≥5, HADS≥8, DRS≥3)
Overall pooled prevalence of clinically significant depressive symptoms of mild/minor severity or
greater (defined as: PHQ8/9≥5, HADS≥8, DRS≥3 (55-57); n = 10) (43-46, 49-54) in people with
extremely short prognoses (N = 905) was 50% (95%CI: 29%-70%) (Figure 2). There was high
heterogeneity (I2 = 97.6%).
Meta-regression found no significant differences between prevalence of depressive symptoms
measured by different tools (p = 0.774). Differences in tools also did not account for the high
heterogeneity among studies (Adjusted R2 = -12.40%). Interestingly, DRS≥3 appeared to yield lower
prevalence of depressive symptoms of 21% (95%CI: 17%-25%; n = 1). Removal of the prevalence
data from DRS≥3 raised overall pooled prevalence to 53% (95%CI: 37%-70%) and reduced
heterogeneity slightly (I2 of 93.1%) (extremely short prognoses sample: N = 547).
2. ≥Moderate or Major Severity (PHQ8/9≥10, HADS≥11)
When performing sub-group analyses on depressive symptoms with the severity cut-off of moderate
or more (PHQ8/9≥10 or HADS≥11 (56, 57); n = 7), pooled prevalence of clinically significant
depressive symptoms in people with extremely short prognoses (N = 476) was 55% (95%CI: 37% 74%) (43, 44, 49-51, 53, 54). Heterogeneity was still high (I2 = 93.4%). (Prevalence data from DRS≥3
was not included in subgroup analysis as DRS≥3 contained both major and minor depressive
symptoms) (55).
There was no statistically significant difference (p = 0.36) between pooled prevalence measured by
PHQ8/9≥10 (47% [95%CI: 23%-71%]) and that by HADS≥11 (64% [95%CI: 40%-89%]), accounting for
only 4.2% of the study heterogeneity in the greater or equal to moderate severity sub-group (metaregression adjusted R2 = 4.2%).
Common Disorders by DSM Diagnostic Criteria
Prevalence of depressive symptoms defined by common disorders through diagnostic criteria
(DSMIIIR/IV/V) included:
•

Major depression (Major depressive disorder / episode; n = 3) (4, 47, 54):

On meta-analysis, the pooled prevalence of major depression in people with
extremely short prognoses (N = 308) was 10% (95%CI: 4%-16%; extremely short
prognoses sample size: N = 308; Figure 3).
o Heterogeneity among studies was only moderate (I2 = 57.5%).
Minor depression (n = 1) (47): 5% (95%CI: 2%-8%; extremely short prognoses: N = 200)
o

•

Longitudinal Changes
In five longitudinal studies, data for longitudinal changes in prevalence of clinically significant
depressive symptoms over the 3-6 months before death could be extracted in two studies (43, 44).
Tang et al (2016) reported increasing prevalence of clinically significant depressive symptoms
(defined by HADS ≥11) in Chinese cancer patients as days to death approached from 44.58 % (181–
365 days), 49.91 % (91–180 days), 69.44 % (31–90 days), to 82.64 % (1–30 days) (43). Rabkin et al
(2009), also in the cancer population but in United States, reported a prevalence of major depression
(using PHQ-9) of 0% at 3 months before death, rising to 29% in the last month of life (44).
Two studies informed the proportion of new onset symptoms in those cases with clinically significant
depressive symptoms and extremely short prognoses, which were 36.3% [four out of 11 – Rabkin et
al (2005)] and 57.1% [four out of seven – Rabkin et al (2009)] (44, 45).

Quality /Risk-of-Bias Assessment
Quality of Individual Studies
Seven of 13 studies did not fulfil at least 1 item of the JBI checklist (Figure 4). The leading source of
bias (not fulfilling specified item criteria) was selection bias (Item 1-5: 21.5%), followed by attrition
bias (Item 9: 15.4%), and detection/measurement bias (Item 6-7: 3.8%). No analysis bias was
identified.
Prevalence by Low Risk-of-Bias Studies
There were only two studies found to have low risk of bias, fulfilling all nine criteria in the JBI
checklist of prevalence studies. These differed in country of study and method of depression
identification (48, 49).
Despite these differences, they both had the same depression prevalence of 47%: Stromgren et al
(2002) – study from Denmark using the tool HADS≥11 yielded 47% (95%CI: 39%-55%) (49); and Zhao
et al (2014) – study from China using DSMIV criteria for Depressive Disorders (major & minor
depression, dysthymia and mood disorders due to general medical conditions with depressive
features) found 47% (95%CI: 34%-60%) (48).
Quality across Studies
Each domain of Grading of Recommendations Assessment, Development and Evaluation (GRADE)
was used to assess quality across studies (described below). However, the overall quality score could

not be generated using the online platform for GRADE (GRADEPro), as it was not configured for
systematic reviews of prevalence studies (40, 58, 59).
For risk-of-bias across studies, there were serious limitations due to the general selection bias
intrinsic to researching populations with life-limiting illnesses. Participants were often excluded if
they had significant cognitive impairment or frailty.
For the domain of indirectness, all studies directly addressed their research questions on the
prevalence of depressive symptoms.
Regarding imprecision, there was a lack of established guidance in assessing precision for metaanalyses of prevalence studies. Assuming the use of the width of confidence intervention in the
GRADE approach to assess precision, there was a relatively low precision for prevalence of
depressive symptoms identified by tools (50% [95%CI: 29%-70%]). However, precision was modest
for that identified by diagnostic criteria, with major depression having the widest confidence interval
(10% [95%CI: 4%-16%]). If precision was defined as the sensitivity and specificity of tools used, then
it was relatively high across the studies. All the tools used (PHQ, HADS and DRS) have been
psychometrically tested in the palliative care or oncology settings (55, 60-62).
For inconsistency, there was high heterogeneity across studies for the prevalence of depressive
symptoms by tools (I2 = 93.4%-97.6%), but only modest heterogeneity (I2 = 57.5%) for prevalence of
depressive symptoms by diagnostic criteria for major depression.
To assess for small study effects and publication bias, studies with sample sizes of 100 or less were
removed from meta-analyses. The final pooled prevalence estimates of clinically significant
depressive symptoms by tools (≥ mild severity) (50% [95% CI: 8% – 92%]; I2 = 99.4; n = 3 (43, 49, 52))
and diagnostic criteria for major depression (8% [95%CI: 5.0% - 12.6%]; n = 1 (47)) have not changed
significantly from the estimates that included all studies. Regression (Egger’s) tests of the
corresponding inverted funnel plots again showed no evidence of small study effects or publication
bias for the meta-analyses that included all selected studies: using depression-specific screening
tools (≥mild or minor severity; Egger's Coefficient: 0.87 [95%CI: -7.45 to 9.19); p = 0.815); and
diagnostic criteria for major depression (Egger's Coefficient: 1.04 [95%CI: -36.12 to 38.21]; p = 0.782).

DISCUSSION
High Prevalence of Clinically Significant Depressive Symptoms in Extremely Short Prognoses Setting
This evidence synthesis found high prevalence (one in two individuals) of clinically significant
depressive symptoms in people with extremely short prognoses.
The duration of a median survival of one month (indicated by the functional scores of KPS ≤ 40 or
ECOG 4) with the upper limit of two months was used to differentiate individuals with extremely
short prognoses from others with advanced life-limiting illnesses. This is an important distinction as
this time period is the time during which frailty and symptomatology of the terminal illnesses (e.g.
fatigue, delirium and inability to swallow) significantly escalates, hindering effective depression

assessment and management (19, 24, 25). This extremely short life-expectancy period makes the
conventional depression interventions unlikely to be successful due to their slow onset-of-actions,
and supports the consideration for alternative rapid-onset interventions such as methylphenidate or
ketamine (26, 63, 64).
The prevalence of clinically significant depressive symptoms in advanced life-limiting illnesses using
HADS score ≥11 have been reported in a systematic review to be around 29% (11). This review adds
to the data by finding a higher pooled prevalence of 50% in the sub-group with extremely short
prognoses using depression-specific tools. If only studies with HADS score ≥11 were considered, an
even higher overall pooled prevalence of 64% resulted, including the 47% from the low risk-of-bias
study (49).
Meanwhile, the prevalence of combined depressive disorders in the general advanced illness
population using diagnostic criteria has been reported to be 25% in another systematic review (12).
This is lower than the corresponding prevalence of 47% found using diagnostic criteria in people with
extremely short prognoses in the current review (48). The higher prevalence of clinically significant
depressive symptoms in those with extremely short prognoses is further supported by the findings
of longitudinal studies by Tang et al (2016) (included in this review) and Seow et al (2011), where
both studies reported increases of 33% and approximately 10% respectively in prevalence of
clinically significant depressive symptoms in the last six months of life (19, 43).
Reasons for high prevalence of clinically significant depressive symptoms in people with advanced
life-limiting illnesses and extremely short prognoses are likely multi-faceted. In addition to
individuals having the stressors of advanced life-limiting illnesses and associated adjustment issues,
inadequacy of recognition, assessment and management of these symptoms during life-limiting
illnesses at earlier stages may be a factor. Studies reveal around 40% of clinicians treating people
with advanced life-limiting illnesses do not regularly screen or assess for depressive symptoms, with
as low as 7% of the depressed cases being recognised and up to 70% of affected individuals receiving
inadequate interventions (20, 48, 65-68). There is intrinsic difficulty in assessing depressive
symptoms in individuals whose advanced life-limiting illnesses might mimic depressive symptoms, as
well as challenges in providing interventions likely to be effective in time (1, 26). Further barriers to
suboptimal recognition, assessment and management include: clinicians’ fear of distressing patients,
especially given the stigma associated with psychiatric diagnoses (3, 69); lack of awareness and skills
to detect and manage depression (20, 68, 70-75); perceived lack of resources such as time (20, 68,
76), acceptable assessment tools and access to mental health services (20, 69, 77-82); beliefs that
depression is ‘normal’ (69, 76); and that screening & interventions are likely to be futile in this
context (70, 71, 73, 83). It is possible that addressing these barriers might lead to an earlier
detection and management of depressive symptoms in people with advanced life-limiting illnesses.
This may subsequently lower the prevalence of such when prognoses are extremely short.
Meanwhile, evidence suggests a significant proportion of individuals with advanced life-limiting
illnesses and extremely poor prognose were experiencing clinically significant depressive symptoms
for the first time (36%-57% from Rabkin et al (2005) and Rabkin et al (2009) in this review (44, 45)).
This is also supported by the findings of a trend for building prevalence as death approaches (43, 44).
Given the limitation of having only small number of studies with small sample sizes, these findings
need to be interpreted with caution. The findings should not be perceived as definitive but

hypothesis generating. The exact prevalence of new-onset cases needs to be further studied.
Nonetheless, one might also ponder on the underlying drivers for having a substantial proportion of
new cases of depressive symptoms in the last weeks to days of life. It may be possible that the
pathological processes of the advanced life-limiting illnesses themselves such as brain metastases or
hypercalcemia cause depressive symptoms (84). Other potential drivers for new-onset depressive
symptoms may be: the associated distressing symptoms and functional limitations that are often
more marked towards the end-of-life due to disease progression (19, 43, 46, 85); the associated grief
& hopelessness (86); loss of dignity (87, 88); concerns about social relationship (e.g. perceived lack of
support or fear of being a burden to others) (43, 47, 85); and existential distress (88). It would be
instructive to see whether targeting these issues decreases incidence of depressive symptoms in
people with extremely short prognoses in future studies.

Methods of Defining Clinically Significant Depressive Symptoms
The construct of “clinically significant depressive symptoms” in the literature is an interesting one. It
encompasses depressive disorders diagnosed by the conventional diagnostic criteria (27). It also
includes subsyndromal depression where depressive symptoms are severe enough to fulfil certain
thresholds set by various depression-specific screening tool but cannot be diagnosed as specific
depressive disorders using diagnostic criteria (27-30). In fact, the sole use of diagnostic criteria in
assessing for depressive symptoms in the extremely short prognoses setting might underestimate
the true prevalence of these symptoms. Firstly, there may not be enough time for specific depressive
disorder (e.g. two weeks for major depression (9)) to be established due to the short life
expectancies (89). Secondly, up to three-quarters of patients with extremely short prognoses might
to excluded from studies, as the assessment of diagnostic criteria using psychiatric interviews could
be too burdensome, considering their cognitive impairment or frailty (4, 11, 47)). The addition of
using validated depression-specific screening tools in the palliative care setting to identify individuals
with clinically significant depressive symptoms may overcome the issue of missing individuals with
subsyndromal depression by diagnostic criteria. Nonetheless, the use of depression-specific tools
does come with the intrinsic shortfall of “false-positivity”. When used as indirect measurements of
specific depressive disorders, normal anticipatory grief may not be entirely excluded, leading to an
over-estimation of the prevalence of specific depressive disorders (90, 91). Perhaps, a better way to
perceive the use of depression-specific screening tools is not to use them to predict for certain
depressive disorders in this context. Rather, these tools have the value in identifying people who
have clinically significant depressive symptoms at a certain time point that requires clinician
attention and interventions, including those with subsyndromal depression.
There are a myriad of depression specific screening tools . Among these, relatively few have been
validated for use in the palliative care setting. These include: HADS, Single and Two Items Questions
(“Are you depressed?” +/- “Have you lost interest in activities?”), Visual Analogue Scale, Edinburgh
Postnatal Depression Scale, and Beck Depression Inventory-Short Form (91). The current study
identified three tools that were used in people with life-limiting illnesses and extremely short
prognoses: Patient Health Questionnaire 8/9 (PHQ 8/9), HADS and Depression Rating Scale (DRS InterRAI PC). This review and meta-analysis did not observe any statistical differences between them.
This is consistent with the findings by Cameron (2008) and Hansson et al (2009) that demonstrated

similar prevalence of depressive symptoms generated by HADS and PHQ-9 with overall convergent
validity between the two tools, though there was a lack of convergence between the severity cutoffs (56, 57). However, it is possible that, with only a modest number of studies using tools (n = 10),
this study was insufficiently powered to detect the differences between them. Particularly, the one
study that used DRS seemed to have yielded a low prevalence estimate (52). The underlying reason
might be due to the construct of DRS. The DRS was originally designed to detect depressive
symptoms in nursing home residents, for whom assessing patients face-to-face using psychiatric
interviews or self-reported depression-specific tools might be impractical (55). Its scoring depends
on the daily observed standardized mood and behavioural item data collected in the Resident
Assessment Instrument, the Minimum Data Set (55). Different from PHQ-8/9 or HADS, it only
contains three depression-specific items (sad facial expression, tearfulness, and observed negative
statements by residents [passive suicidal ideation]). Four other items are less depression-specific
(anger & irritability, expressions of fears, repetitive health complaints; and repetitive anxious
concerns) (55). Therefore, there is a possibility that DRS under-recognized depressive symptoms in
patients who had other depressive symptom items included in PHQ-8/9 or HADS but did not have
depressed or teary affect, leading to a lower prevalence estimate. The comparison and feasibility of
these tools for the use of detecting clinically significant depressive symptoms in people with
extremely short prognoses warrant further investigation.
In contrast, when exploring the prevalence of depressive symptoms using diagnostic criteria (goldstandard) for specific depressive disorders, the prevalence of major and minor depression
represented a relative minority. Major and minor depressions accounted for only 10% and 5%
respectively of those with extremely short prognoses and clinically significant depressive symptoms.
This reflects the observations that clinically significant mood disturbances are prevalent (around 40%)
but major depression is relatively uncommon in the general cancer or terminal settings (89, 92). In
fact, the prevalence of major depression and other associated mental disorders might not increase
as death approaches (92). Nonetheless, the pooled prevalence of combined depressive disorders
(major & minor depression, dysthymia and mood disorders due to general medical conditions with
depressive features) found in this review was high, at 47% by Zhao et al (2014) (48). This raises the
possibility that much of the clinically significantly depressed individuals with extremely short
prognoses may not be diagnosed with major or minor depression, but rather, be labelled as other
disorders with depressive features (e.g. adjustment disorder) (84). Interestingly, the composite
prevalence of various depressive disorders for people with extremely short prognoses of 47%
seemed to equate to the prevalence of depressive symptoms defined using screening tools (as seen
in the results of the low-risk-of-bias studies and the pooled prevalence of 50%-55% in meta-analyses
using tools) (48, 49). This raises the possibility that, in those with extremely short prognoses, one can
use depression screening tools such as HADS or PHQ to estimate the combined prevalence of various
depressive disorders (and therefore the burden of depression). This would avoid the need to
undergo extensive psychiatric interviews as required by the diagnostic criteria for patients for whom
these interviews might be too burdensome and thus not be feasible. This too warrants future study.
In contrast, for diagnostic purposes, these screening tools should not replace diagnostic criteria in
diagnosing depressive disorders (63). Rather, these screening tools are means to help clinicians
identify individuals with clinically significant symptoms needing interventions.
Limitations: Quality Assessment/Risk-of-Bias

The predominant types of risk of bias across studies in this review, consistent with the other similar
systematic reviews exploring the prevalence of depressive symptoms in advanced life-limiting
illnesses, were selection and attrition (non-responder) biases (11, 12). The findings of this review
need to be interpreted considering these biases. In the included studies, a significant proportion of
participants with extremely short prognoses were excluded due to their being significantly
cognitively impaired or too frail to undergo study assessment (even up to 75% in one study) (47).
Given the assessment of depressive disorder is contentious for those with significant cognitive
impairment or dementia, marked by a wide range of prevalence of depressive symptoms, prevalence
studies in the setting of significant cognitive impairment or dementia were excluded in this
systematic review (93-95). More than half of the full texts screened (57%) could not have data for
those with extremely short prognoses extracted with a lack of the functional status or survival data
of interests. There is, therefore, a need for future research involving advanced life-limiting illnesses
to include prognostic or survival measures such as those used in this review. Feasible alternative
methods of assessing for depressive symptoms in this context also need further investigation.
Another limitation of this review is that studies that used general symptom measurement scales
with non-specific depression measurement such as the Edmonton Symptom Assessment System
Depression Score (ESAS) were excluded (19, 21). This was to ensure measurement accuracy.
However, prevalence of depressive symptoms in people with extremely short prognoses captured by
ESAS in Seow et al, 2011 (36%) and Liu et al, 2013 (41.7%) were consistent with results of this
systematic review (19, 21). This raises the possibility that ESAS may be a feasible screening tool for
depressive symptoms in people with extremely short prognoses.
Similar to other systematic reviews reporting prevalence of depressive symptoms in palliative care,
this systematic review is limited by the high heterogeneity of the included studies (11, 12). Due to
the small number of studies included (n = 13) and many studies having a combination of variables
(e.g. a combination of malignant and non-malignant diseases or mixed recruitment settings),
extensive investigation of potential moderators that account for heterogeneity using metaregression cannot be performed with statistical validity. Nonetheless, one can postulates that the
majority of heterogeneity is contributed by the same factors listed in other similar systematic
reviews: the various populations studied, assessment methods and depression definitions (11, 12).
Strengths and Other Limitations
Firstly, the results reported by this review represents possibly the largest number of people with
extremely short prognoses (N = 1245) in the current literature. This review utilised inclusive search
strategies to include the broader population of advance life-limiting illnesses that would not
necessarily have been referred to palliative care, as well as both malignant and non-malignant
disease. However, there is a relative lack of representation of studies focusing on non-malignant
disease. This is because many screened non-malignant studies did not include a measure of
functional status, especially later in people’s disease trajectory. Additionally, there was a lack of
studies that reported the prevalence findings of malignant or non-malignant diseases separately.
Therefore, comparison of prevalence estimates between studies with malignant versus nonmalignant disease has not been possible.
An important limitation of this review is the inclusion of studies with small sample sizes into the
meta-analysis, introducing the risk of small study effects and publication bias (96-98). Nonetheless,

inverted funnel plots and Egger’s regression tests have demonstrated the lack of small study effects.
The removal of studies with sample sizes of 100 or less from meta-analyses have demonstrated
comparable findings (96). Perhaps, in this context, a robust estimation of prevalence would be
achieved through including all available evidence, as limiting studies due to small study size may
introduce subjectivity to the final result (99). However, the lack of sample size in individual studies
have contributed to the overall limited precision of the prevalence estimates. This is indicated by the
wide confidence intervals of the prevalence data.
A strength of this review is that the prevalence of clinically significant depressive symptoms has been
explored by considering various methods of detection (utilising depression-specific screening tools
and different diagnostic criteria through psychiatric interview). This ensures that the pooled
prevalence better reflects the overall global burden of depressive symptoms experienced by this
sub-population.
Another major strength of this study is that this is one of the few reviews with meta-analysis of
prevalence that uses formal guideline to critically appraise individual studies (JBI Systematic Reviews
Checklist for Prevalence Studies) and across studies (GRADE approach), for the first guideline
established to appraise individual prevalence studies was only published in 2017 (37-40). For quality
assessment across studies, GRADE approach has been frequently utilised for meta-analysis of causeand-effect and diagnostic tools (40, 58, 100). However, it has yet to be adapted for the use of
assessing prevalence studies (59). Therefore, this systematic review has used the general principles
of the GRADE approach to perform quality assessment across studies. The overall GRADE score has
not been generated in this review to allow the opportunity for objective judgments by the readers.

Implications
The findings of the increase in prevalence as death approaches with up to half of the people with
extremely short prognoses having clinically significant depressive symptoms have major implications
for clinical practice, policy makers & funders, and future research.
Implication for clinical practice
There is a need for some forms of systematic processes (e.g. screening for depressed mood on first
contact with palliative care services) to increase clinicians’ awareness of potentially depressed
individuals, as the affected individuals might be reluctant to report symptoms of depression due to
social stigma (3, 11, 20). Patients and families may need to be encouraged to talk about their mood
by clinicians, and certain components of the depression screening tools might be helpful to act as
prompts (e.g. using PHQ-9 to ask about anhedonia).
Emphasis must be placed on clinicians to not neglect patients’ concerns of depressed mood in the
context of having extremely short prognoses as ‘normal reactions’ to the dying process. Clinicians
need to be aware that there is a high likelihood of these patients suffering from depressive
symptoms that significantly impair their quality-of-life without meeting the diagnostic criteria of
various depressive disorders (subsyndromal depression). The disclosures of these symptoms from
patients, therefore, need to be thoroughly explored and addressed, with the expression of
depressive symptoms encouraged and de-stigmatised (3). Individuals with subsyndromal depression

may still benefit from various psychological support interventions to prevent more severe depressive
symptoms and disorders from developing (63). In fact, given the high prevalence of these symptoms,
there is an argument that all patients with extremely short prognoses should be offered empathic
non-pharmacological supportive services (e.g. counselling / supportive psychotherapy) as primary
prevention for possible depressive symptoms, and have the escalation of treatments as deemed
appropriate.
Implication for policy makers and funders
The high prevalence of clinically significant depressive symptoms in this subgroup of extremely short
prognoses necessitate the treating clinicians to be trained and empowered for timely assessment
and management of depressive symptoms. The clinical culture needs to be one that offers
supportive environment to staffs engaging with depressed patients (e.g. allowing extra time in clinic
for depression assessment, offering de-briefing sessions for staffs). Integration between palliative
care and psychiatry may improve the tendency of under-recognition of depressive symptoms,
leading to better depression care (101-103). Public health interventions aiming at improving public
awareness of mood health at the end-of-life, de-stigmatising depressive symptoms and encouraging
open discussion are also required (3).
Implication for future research
This review highlights the needs for further research in people with advanced life-limiting illnesses
and extremely short prognoses as studies focusing on this subpopulation as their primary objectives
are lacking. The wide confidence intervals of prevalence estimates found in this study reflects the
lack of any agreed nation or international criteria for referral to hospice / palliative care services, and
the relatively poor estimation of people’s prognosis by many clinicians (10). Importantly, this
systematic review and meta-analysis forms an important first step to create a platform for more
uniform population eligibility definitions for future, larger studies. The validity and acceptability of
using functional scores as prognostic indicators for extremely short prognosis in non-malignant
diseases needs to be further explored.
For depression research in this subpopulation, more prospective longitudinal studies are required to
estimate the new occurrences of depressive symptoms better in individuals with extremely short
prognoses. Identifying a feasible and acceptable screening tool and assessing the benefits of
implementing screening is vital. The optimal method of assessing depressive symptoms, accounting
for the possibility of patients not fulfilling certain components of the conventional diagnostic criteria
due to the short life expectancy, and the feasibility and acceptability of the substitute approach of
diagnosis (i.e. Endicott Criteria) need further exploration (104). Clinicians’ perspectives on assessing
and managing depression in this context, as well as the corresponding views from patient and their
families also require study.
CONCLUSION
Clinically significant depressive symptoms (including subsyndromal depression) are common in
people with advanced life-limiting illnesses and extremely short prognoses (approximately 50%).

Clinicians caring for people with extremely short prognoses need to be proactive in the recognition
and assessment of these symptoms to allow for timely interventions. Much research is required to
establish effective assessment and management strategies in this field.
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Table 1.
Characteristics of included studies
Author
Year

Location,
Country

Study Design

Source Population Eligibility / Recruitment Setting

Diagnoses

Demographics of
Source Population
(Total number
[N), Age, Gender)

Sampling
Method

Definition of Extremely Short Prognoses
/ Number from Source Population

Depression Definition / Assessment Timing &
Method

Number (n) and
Prevalence (%) of Clinically
Significant Depressive
Symptoms in People with
Extremely Short Prognoses

Alamri et
al 2017
(54)

Jeddah,
Saudi Arabia

Prospective
Cross-sectional
Prevalence Study

Elderly patients aged 60 years and older admitted to
the medical (51%) and surgical wards (49%) of a
single university hospital.

Cancer (not
otherwise specified)
and mixed nonmalignant diseases
(Cardiovascular,
gastrointestinal,
genitourinary,
infectious, metabolicendocrine,
musculoskeletal,
neurological,
respiratory, and
other)

N = 200

Consecutive

Hospital mortality /Survival (Author
responded in email stating all those with
hospital mortality had survival <60 days)

1. Self-administered PHQ-9:
• ≥10: “major depression”
• ≥ 5-9: “other depressive disorders”

PHQ-9 ≥10: n = 6 (31.6%)

Cancer (not
otherwise specified)

N = 92

Exclusion: severe cognitive dysfunction, acute
psychosis, bipolar disorder, schizophrenia, language
barrier, aphasia, hearing impairment, reduced level
of consciousness, or unstable medical illnesses

Breitbart
et al 2000
(4)

New York,
United
States

Prospective
Cross-sectional
Prevalence study

Hospitalized, terminally ill cancer patients recruited
after admission to a 200-bed palliative care hospital
with life expectancy of less than 6 months.

Mean age: 70.2
(SD: 8.1)
N = 19

Male = 41.0%

Unclear

Mean age: 65.9
(SD: 15.6)
Inclusion: English speaking; sufficiently cognitively
intact to provide informed consent and valid data;
and were not considered likely (by their physician) to
suffer psychological harm from participation.

Survival with average time until death
was 28 days

N = 89

2. Structured clinical interview with DSMV for
“major depressive disorder”

PHQ-9 ≥ 5-9: n = 2 (10.5%)

Within 48 hours of hospital admission by a trained
research team member.

DSMV Major Depressive
Disorder: n = 1 (5.3%)

DSMIV for “major depressive episode”

DSMIV major depressive
episode: n = 15 (16.9%)

After admission jointly by two investigators via
structured clinical interview (interrater reliability
coefficients 0.55).

(interviews could not be completed for 3
subjects)
Male = 40.0%

Exclusion: Mini-Mental State Examination score
below 20.

Chan et al
2012 (53)

Hong Kong,
China

Prospective
Cross-sectional
study

Adult patients (≥18 years) with advanced (Stage IIIIV) gynaecological malignancy in the palliative phase
admitted to the palliative care unit of Grantham
Hospital, Hong Kong.

Gynecological
cancers (ovary,
cervix, uterus)

N = 53

Mean age: 62.1
(SD: 15.5)
Inclusion: Chinese descent; fluent in the Cantonese
dialect; and being capable of giving informed consent
to participate in the study.

Exclusion: Unable to complete the questionnaires
due to either physical or cognitive limitation; and

Male = 0%

Consecutive

Functional status: median PPS = 40

N= 53

HADS (Chinese Cantonese version – Cronbach’s
α=0.77):
• 8 to 10: “doubtful case”
• 11 or higher: “definite case”
• 15 or higher: “severe depression”

Within 3 days of admission interviewed by
principal investigator

HADS score:
• 11 or higher “definite
case”: n = 33 (62.2%)
• 15 or higher “severe
depression”: n = 10
(19%)

being unable to communicate either verbally or in
writing.

Chochinov
et al 1995
(47)

Winnipeg,
Canada

Prospective
longitudinal
prevalence study

Terminal cancer adult patients from palliative care
units of two hospitals in Winnipeg, Canada.

Exclusion: Cognitively impaired and unable to give
informed consent or were too gravely ill to take part
in a detailed interview.

Mix cancer types
(lung,
gastrointestinal,
genitourinary breast,
hematological and
other)

N = 200

Unclear

Survival: Median of 43 days
Functional status: mean KPS 40

Mean age: 70.9
(SD: 10.6)
N = 200

Male = 48.5%

Fisher et al
2014 (52)

Ontario,
Canada

Prospective
Cross-sectional
Prevalence Study

Home care palliative care adult patients in 6 of 14
sites in Ontario involved in pilot implementation of
new palliative care need assessment tool (InterRAI
Palliative Care) with a mix of malignant and nonmalignant diseases.

Cancer (not
otherwise specified)
and non-malignant
diseases
(Cardiovascular,
Chronic Obstructive
Pulmonary Disease,
and other)

*”Participants were classified as palliative by the
home care case manager if they were no longer
responsive to curative treatment, considered to be
dying, and the goal of care was to alleviate
distressing symptoms in the last stage of their illness”

DSMIIIR: Major and Minor Depressive Episodes

N = 5144

Unclear

Average age of
70.0 (range: 19.6 –
107.2; two-thirds
of the sample >
age 65)

Survival: Estimated prognosis <6 weeks

One week or more after admission using semistructured diagnostic interview administered by a
trained psychiatric nurse, clinical psychologist or a
psychiatrist. Two-week follow-up interview
conducted only for those with desire to die at the
initial interview. Inter-rater reliability measured by
having second rater attend 13.5% of random
sample interview (kappa 0.76).

Depression Rating Scale (DRS) (InterRAI Palliative
Care) ≥ 3 for “Depressive Symptoms”

N = 358
Assessor rating at time of assessment not
otherwise specified

DSMIIIR:
• Major depressive
episode: n = 16 (8%)
• Minor depressive
episode: n = 9 (4.5%)

*Cannot extract
prevalence data of
extremely short prognosis
on the two week follow-up
time point (as only those
with desire for death were
re-assessed and reported).
Table 1:
“Depressive Symptoms” by
Depression Rating Scale
(DRS) (InterRAI Palliative
Care) ≥3: n = 74 (20.7%)

Male = 49.1%

Exclusion: Significant cognitive impairment (i.e.,
Cognitive Performance Score [CPS] < 4); Unable to
give informed consent
Hartung et
al 2017
(51)

5 regions
across
Germany

Prospective
Cross-sectional
Prevalence study

Adults (age 18 through 75), proficient in German,
with cancer from a mixture of clinical settings - total
of 84 inpatient oncology wards, outpatient clinics,
cancer rehabilitation centres in five distinct regions
across Germany (Freiburg, Hamburg, Heidelberg,
Leipzig and Würzburg).

Exclusion: Cognitive and verbal impairments that
interfered with ability to give informed consent.

Mix cancer types
(thyroid, brain,
pancreas,
hematological,
female genital
organs, bladder, lung,
stomach/esophagus,
head and neck, soft
tissue, breast, testis,
kidney/urinary tract,
colon/rectum,
hepatobiliary,
melanoma, prostate,

N = 4020

Mean age: 58

Consecutive

Functional status: ECOG4

PHQ-9 ≥10 for “depressed” (German version of
the self-report measure)

N = 13
Timing of assessment not specified

(SD: 11)

Male = 48.6%

“Depressed” by PHQ-9 ≥
10: n = 6 (46.2%)

other)
Hopwood
&
Stephens
2000 (46)

United
Kingdom

Prospective –
Longitudinal
Prevalence Study
using data from 3
RCTs

Adults with lung cancer (non-small-cell and small-cell
lung cancers) from three multicentred RCTs by
United Kingdom Medical Research Council Lung
Cancer Working Party: two chemotherapy trials
(LU12 and LU16) and one radiotherapy trial (LU13).

Non-small-cell and
small-cell lung
cancers

N = 1189 (Male =
69.8%), consisted
of the below:

Random

Functional status: WHO PS 4

HADS for “Depression” (“Borderline” or “Case”):
• 8-10: “Borderline”
• ≥11: “Case”

“Depression” (case or
borderline score) by HADS
≥8 at baseline: n = 6
(55.0%)

N = 11
HADS assessed at baseline and at first follow-up

LU12
(Chemotherapy
trial for small-cell
lung cancer):

*Cannot extract data of
extremely short prognosis
on the first follow-up time
point (High attrition rate
with WHO PS 4 prevalence
data not reported)

N = 310
Median age: 65
(Range 39-90)
Male = 63%

LU 16
(Chemotherapy
trial for small cell
lung cancer)
N = 370
Median age: 67
(Range 35-83)
Male = 63%

LU13
(Radiotherapy trial
for Non-small-celllung cancer)
N = 509
Median age: 66
(Range: 33-89)
Male = 79%

Que et al
2013 (50)

Manila,
Philippines

Prospective
Cross-sectional
Prevalence Study

Adults oncology inpatients and outpatients
presented for cancer treatment at a single non-profit
tertiary hospital in Manila, Philippines.

Mixed Cancer Types
(breast, head and
neck, lung, brain,
lymphoma,
leukemia)

N = 271

Unclear

Functional status: ECOG 4

“Depression” by PHQ-8 (excludes the item on
suicidal ideation) ≥10 (Cronbach’s α = 0.84)

“Depression” by PHQ-8
≥10: n = 6 (86%)

*Age ≥ 53 = 53.5%

N=7

Timing of assessment (survey) not specified

Survival: Median interval between time of
last monthly interview and death = 30
days

Major and Minor Depression by PHQ-9*:

*Male = 36.5%

(*Age & Gender
data extrapolated
from table 2 of
article)
Rabkin et
al 2005
(45)

New York,
US

Prospective
Longitudinal
Prevalence Study

Hospice eligible adult patients with late stage
amyotrophic lateral sclerosis (ALS) indicated by FVC
<50% (“a value related to the risk of hospice
admission and death or the need for mechanical
ventilation within 6 months”) from multiple sites
(though 94% enrolled from a single ALS Research
Centre) (setting not otherwise specified).

Late-stage
amyotrophic lateral
sclerosis

N = 80

Unclear

Age ranged from
27 to 85, 20%
were under age
50, and one-third
were over 70

Exclusion: dementia; inability to speak English;
absence of nonpaid caregiver who agreed to
participate; use of mechanical ventilation at baseline;
inability to communicate at least “yes” and “no,”;
lived outside 3-hour drive from medical centre.

N = 53

• Major Depression: ≥5 items with score ≥2
with ≥ 1 item being depressed mood or
anhedonia
• Minor Depression: ≥3 items with score ≥2
with ≥ 1 item being depressed mood or
anhedonia

Depression (Both major
and minor Depression) by
PHQ-9≥6: n = 17 (32.1%)

*Authors departed from the standard scoring on
three items of PHQ-9 that were sometimes
directly caused by ALS: sleep problems, poor
appetite, and psychomotor retardation when
considered inappropriate, and prorated the
remaining items to generate a total score.

Male = 56%

Scheduled monthly interviews almost always at
home until patients met a study endpoint of
tracheostomy or death

Rabkin et
al 2009
(44)

New
York/San
Francisco,
United
States

Prospective
Longitudinal
Prevalence Study

Cancer patients with prognosis of 6-12months from
oncology services of multiple sites and home care
service of a community hospital.

Mixed cancer types
(breast, lymphomas,
colorectal, lung,
pancreas and other)

Copenhagen
, Denmark

Prospective
Feasibility
/Cross-sectional
Prevalence study

Danish speaking adult patients with advanced cancer
for which no curative or life-prolonging treatment
could be offered and referred/admitted to the
palliative care services of a Copenhagen hospital
(Mixture of inpatient, outpatient and home care
palliative care services).

Convenience

Age and gender of
the cohort not
reported

Exclusion: Non-English speaking; insufficient
cognitive capacity to consent to study; had no a
family member or close friend who served as a nonpaid caregiver and who agreed to participate; not
lived at home within an hour drive from the
respective medical centre at study entry
Stromgren
et al 2002
(49)

N = 58

Mixed cancer types
(brain, head and
neck, gastrointestinal
tract, respiratory,
breast, genitourinary,
gynecological,
sarcoma,
melanoma/skin,

N = 176

Age: mean 62.9
(No SD reported);
median 63

Survival: Median interval between final
assessment and death = 28 days

“Major depressive disorder” by PHQ-9 ≥10: (≥ five
items including depressed mood or loss of interest
must be scored 2 or 3) (Cronbach α = 0.79)

Major depressive disorder
by PHQ-9 ≥10: n = 7
(29.2%)

N = 24
Assessment by interviews almost always at home
scheduled at approximately 1-month intervals
until death or the study ended

Consecutive

Survival from first contact with
department: Median 35 days

Functional status: Median KPS 40

“Depression (Definite case)” by HADS ≥ 11

Assessed via self-assessment questionnaire at first
contact with the palliative care department.

Depression (Definite case)
by HADS ≥ 11: n = 63
(47.0%)

hematologic,
unknown)

(Range: 37-91)
N = 134

Exclusion: No informed consent; staff judged the
patient too ill to participate
Gender: Male =
43.8%

Tang et al
2016 (43)

Taiwan

Prospective
Longitudinal
prevalence study

Adult (≥20 years old) oncology patients with terminal
stage cancer and palliative intent treatment
(unresponsive to curative cancer treatment and
continuing to progress) from medical inpatient units
of a medical centre in Taiwan

Mixed cancer types
(lung, liver-pancreas,
head and neck,
other)

Beijing,
China

Prospective
Cross-sectional

Consented adult (≥18 years) cancer patients from
the inpatient oncology ward of a hospital in Beijing

Study
Exclusion: Too frail or unwell to be interviewed;
obvious cognitive impairment based on a brief
clinical interview performed immediately before the
administration of the Mini International
Neuropsychiatric Interview (MINI) 5.0; severe
hearing/speech impairment that would make the
interview infeasible; being unaware of cancer
diagnoses

Convenience

Age over 56 years
old = 58.5%

Exclusion: Cognitively incompetent as evaluated by
their primary physicians; ability to communicate
coherently with data collectors.

Zhao et al
2014 (48)

N = 325

Survival - Time before death of 1-30 days

“Severe Depressive Symptoms” by HADS scores
≥11

“Severe Depressive
Symptoms” by HADS
scores ≥11: n = 192 (82%)

N = 233
Participants were interviewed while hospitalized
or waiting for outpatient visits approximately
every 2 weeks until they declined to participate or
died.

Male = 57.5%

Mixed cancer types
(lung, digestive tract,
breast, liver, ovarian,
uterine and other)

N = 460

Mean age: 59.4
(SD: 12.0); Range:
20-99

Male = 49.1%

Consecutive

Functional status: ECOG 4

N = 51

“Depressive Disorders*” by DSMIV ascertained by
Chinese version of the Mini International
Neuropsychiatric Interview (MINI) 5.0 by eight
trained psychiatrists (coefficients of interrater and
test–retest reliability were 0.92 and 0.98
respectively).

“Depressive Disorders*” by
DSMIV (MINI): n = 24
(47.1%)

*Depressive disorders
included: major depressive
disorder (MDD),
*Depressive disorders included: major depressive
disorder (MDD),
dysthymia, minor depressive disorder, mood
disorder due to a general medical condition with
major depressive-like episode or with depressive
features; and mood disorder due to substances
with depressive features.

dysthymia, minor
depressive disorder, mood
disorder due to a general
medical condition with
major depressive-like
episode or with depressive
features; and mood
disorder due to substances
with depressive features.

Time of assessment by psychiatrists while as
inpatients was not otherwise specified.
ABBREVIATIONS: ALS: Amyotrophic Lateral Sclerosis; CPS: Cognitive Performance Score; DRS: Depression Rating Scale (InterRAI Palliative Care); DSM: Diagnostic and Statistical Manual of Mental Disorders; ECOG: Eastern Cooperative Oncology Group Performance Status; FVC: Forced Vital Capacity; HADS: Hospital
Anxiety and Depression Scale; KPS: Karnofsky Functional Performance Status Scale; MDD: Major Depressive Disorder; MINI: Mini International Neuropsychiatric Interview; PHQ: Patient Health Questionnaire; PPS: Palliative Performance Scale; PHQ: Patient Health Questionnaire; RCT: Randomized Controlled Trial; SD:
Standard Deviation; WHO PS: World Health Organization Performance Status

Table 2.
Study demographics of included studies (n=13)
Study Characteristics
Study Design
Prospective
Longitudinal (43-47)
Cross-sectional (4, 48-54)
Country
Saudi Arabia (54)
Philippine (50)
China (Beijing/ Hong Kong/Taiwan) (43, 48, 53)
United States (4, 44, 45)
Canada (47, 52)
United Kingdom (46)
Germany (51)
Denmark (49)
Recruitment Settings
Inpatient only
General (43, 48, 54)
Palliative care specific (4, 47, 53)
Outpatient only
Home care only
General
Palliative care specific (52)
Mixed settings
General (44, 50, 51)
Palliative care specific (49)
Others
Setting not otherwise specified (45, 46)
Diagnoses
Combination of malignant and non-malignant
conditions (52, 54)
Malignant only (4, 43, 44, 46-51, 53)
Combination of early and advanced cancer
types (50, 51)
Advanced / terminal cancer (mix types) (4,
43, 44, 47, 49, 84)
Advanced gynecological cancer (palliative
phase) (53)
Lung cancer (small cell & non-small cell) on
palliative chemo /radiotherapy (46)
Non-malignant
Late stage amyotrophic lateral sclerosis (45)
Age
Mean age
Gender

Number of Studies (n out of 13) / Study
Descriptions
13
5
8
1
1
3
3
2
1
1
1
6
3
3
0
1
0
1
4
3
1
2
2
2
10
2
6
1
1
1
1
58-70.9 among nine studies (4, 47-49, 51-54)
(Five studies did not report mean age)

Male %

Definition of Extremely short prognoses
1. Functional status (46-51, 53)*
ECOG4 (48, 50, 51)
WHOPS4 (46)
PPS≤50 (53)
KPS≤40 (47, 49)
AKPS≤40
2. Survival (4, 43-45, 47, 49, 52, 54)*
Days prior to death (43, 52, 54)
Average survival (days) (4, 44, 45, 47, 49)

36.5% – 69.8% (11 studies)
(One study has 0% male (gynaecological cancer
study (53); and one study did not report gender
(44))
7
3
1
1
2
0
8
3 (Range: 1-60 days)
5 (Range: 28 to 43 days - medians used apart
from one study where average is reported but
the type not specified (4))

Definition of Clinically Significant Depressive
Symptoms
1. Tools (43-46, 49-54)Δ
10
PHQ (44, 45, 50, 51, 54)
5
PHQ9(44, 45, 51, 54)
4
Score≥10 as major depression (44,
4
45, 51, 54)
Score 5-9 as other depressive
2
†
disorders (45, 54)
PHQ8≥10 (no suicide item) (50)
1
HADS (43, 46, 49, 53)
4
HADS≥11 as depression (43, 46, 49, 53)
4
HADS≥8 as borderline depression (46)
1
DRS≥3 (InterRAI PC) (52)
1
2. Criteria (4, 47, 48, 54)Δ
4
DSM (4, 47, 48, 54)
4
DSMV (54)
1
DSMIV (4, 48)
2
DSMIIIR (47)
1
ICD
0
Endicott
0
3. Conditions by DSM (4, 47, 48, 54)
4
Major depressive disorder/episode (4, 47,
4
48, 54)
Minor depressive disorder/episode (47, 48) 2
Dysthymic disorder (48)
1
Mood disorder due to general medical
1
condition with depressive features (48)
Footnotes: *2 studies had both functional status / survival (47, 49); †Rabkin et al, 2005 uses 3 or
more PHQ9 items with score ≥2 as minor depression (45);Δ1 study had both DSMV + PHQ9 (54)

Figure 1.
PRISMA Flow Diagram (33)

Caption: PRISMA diagram: 7957 studies were identified through the electronic databases. After removal of
duplicates, 5531 studies underwent title and abstract screening, leaving 500 studies for full-text screening. Following
this, only 13 studies were included for data extraction. Out of the 478 articles excluded: 57.1% (278 out of 487) of
full-text screening studies did not have data on the sub-group of interest (people with extremely short prognoses);
149 articles had no full text (majority were abstracts or posters only); 16 were not English; 13 were systematic
reviews/ meta-analyses; 12 were further duplicate identified; 4 were not an original study; 3 had no prevalence of
depression; 2 were thesis; 3 were general score without depression specific measures; and 1 study had depression
group not specified well enough.

Figure 2.
Prevalence of clinically significant depressive symptoms in people with advanced life-limiting illnesses and
extremely short prognoses identified by depression-specific screening tools.

Caption: Overall pooled prevalence of clinically significant depressive symptoms of mild/minor severity or greater
(defined as: PHQ8/9≥5, HADS≥8, DRS≥3(55-57); n = 10) (43-46, 49-54) in people with extremely short prognoses (N =
905) was 50% (95%CI: 29%-70%). Heterogeneity was high (I2 = 97.6%). For the subgroup with moderate severity or
more (PHQ8/9≥10 or HADS≥11(56, 57); n = 7): Pooled prevalence was 55% (95%CI: 37% - 74%; N = 476) (43, 44, 4951, 53, 54). Heterogeneity was high (I2 = 93.4%).

Figure 3.
Pooled prevalence of major depression in people with advanced life-limiting illnesses and extremely short
prognoses (n = 3; extremely short prognoses N = 308).

Caption: On meta-analysis, the pooled prevalence of major depression in people with extremely short prognoses (N
= 308) was 10% (95%CI: 4%-16%; extremely short prognoses sample size: N = 308) (4, 47, 54).

Figure 4.
Risk of bias assessment using Joanna Briggs Institute (JBI) Systematic Review Checklist for Prevalence Studies (37,
38).
JBI Checklist for Prevalence Studies (Items 1-9)*
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*Joanna Briggs Institute Systematic Review Checklist for Prevalence Studies Items 1-9 (Options:
'Yes'; 'No'; 'Unclear'; and 'Not Applicable'):
1. Was the sample frame appropriate to address the target population?
2. Were study participants sampled in an appropriate way?
3. Was the sample size adequate?
4. Were the study subjects and the setting described in detail?
5. Was the data analysis conducted with sufficient coverage of the identified sample?
6. Were valid methods used for the identification of the condition?
7. Was the condition measured in a standard, reliable way for all participants?
8. Was there appropriate statistical analysis?
9. Was the response rate adequate, and if not, was the low response rate managed
appropriately?
Overall appraisal: Include; Exclude; Seek further info (All 13 studies were included)
CAPTION: Seven out of 13 studies did not fulfil at least 1 item of the checklist. Only two studies were found to have
low risk of bias, fulfilling all nine criteria. The leading source of bias (not fulfilling specified item criteria) was selection
bias (Item 1-5: 21.5%), followed by attrition bias (Item 9: 15.4%), and detection/measurement bias (Item 6-7: 3.8%).
No analysis bias was identified.

